From: Efficacy and safety of co-trimoxazole in eradication phase of melioidosis; systematic review
Name | Study type | Drugs | Sample size | Open or blind | Dose | Duration of eradication phase | Relapse rate | Mortality rate | |
---|---|---|---|---|---|---|---|---|---|
Culture positive | Clinical relapse | ||||||||
Chaowagul et al. [34] | RCT | 1.Co-trimoxazole, doxycycline, chloramphenicol | 91 | Open | Co- trimoxazole (8mg TMP and 40mg SMX/kg/ daily; max 160mg TMP and 800mg SMX/twice daily | 12 weeks | 11.8% | Â | 14% |
2.Co-trimoxazole (TMP/SMX), doxycycline | 89 | Â | 5.4% | Â | 11% | ||||
Rajchanuvong et al. [35] |  | 1.Chloramphenicol, doxycycline, Co-trimoxazole | 52 | Open | Co-trimoxazole (10mg TMP + 50mg SMX/kg/day in 2 divided doses) | 20 weeks | 10% |  | 1.92% |
2. Doxycycline | 49 | 36% | Â | 8.16% | |||||
Anunnatsiri et al. [36] | RCT | Co-trimoxazole | 12 week – 322 | Open |  < 40 kg, the dose used was 160/800 mg of TMP/SMX twice daily; for a body weight of 40–60 kg, the dose was 240/1200 mg of TMP/SMX twice daily; and for a body weight > 60 kg, the dose was 320/1600 mg of TMP/SMX twice daily | 12 weeks | 2% |  | 0.3% |
20 weeks | 20 weeks | 1% | Â | 3% | |||||
Chetchotisakd et al. [37] | RCT | 1.Co-trimoxazole, placebo | 311 | Double blind | TMP-SMX (80 mg TMP and 400 mg SMX) tablets were prescribed using a weight-based dose, bodyweight less than 40 kg or eGFR 15–29 mL/min, 160 mg TMP and 800 mg SMX twice daily; bodyweight of 40 kg to 60 kg, 240 mg TMP and 1200 mg SMX twice daily; and bodyweight greater than 60 kg, 320 mg TMP and 1600 mg SMX twice daily | 20 weeks | 16% | 3% | 3% |
2.Co-trimoxazole, Doxycycline | 315 | 21% | 8% | 1% | |||||
Chetchotisakd et al. [4] | RCT | 1. Ciprofloxacin and azithromycin | 32 | Open | Co- trimoxazole (10mg TMP + 50mg SMX/kg/day in 2 divided doses) | 12 weeks | 22% |  | 3.12% |
2. Co-trimoxazole and doxycycline | 33 | 20Â weeks | 3% | Â | 0% | ||||
Chaowagal et al. [38] | RCT | 1. Co-trimoxazole, doxycycline, chloramphenicol | 91 | Open | Co- trimoxazole (8mg TMP and 40mg SMX/kg/ daily; max 160mg TMP and 800mg SMX/twice daily | 12Â weeks | 2% | 5.9% | 4.4% |
 | 2.Doxycycline | 89 | 5.6% | 13% | 6.74% | ||||
Chaowagul et al. [34] | RCT | 1.Co-trimoxazole, doxycycline, chloramphenicol | 91 | Open | Co- trimoxazole (8mg TMP and 40mg SMX/kg/ daily; max 160mg TMP and 800mg SMX/twice daily | 12Â weeks | 11.8% | Â | 14% |
2.Co-trimoxazole (TMP/SMX), doxycycline | 89 | Â | 5.4% | Â | 11% | ||||
Rajchanuvong et al.[35] |  | 1.Chloramphenicol, doxycycline, Co-trimoxazole | 52 | Open | Co-trimoxazole (10mg TMP + 50mg SMX/kg/day in 2 divided doses) | 20 weeks | 10% |  | 1.92% |
2. Doxycycline | 49 | 36% | Â | 8.16% | |||||
Anunnatsiri et al. [36] | RCT | Co-trimoxazole | 12 week – 322 | Open |  < 40 kg, the dose used was 160/800 mg of TMP/SMX twice daily; for a body weight of 40–60 kg, the dose was 240/1200 mg of TMP/SMX twice daily; and for a body weight > 60 kg, the dose was 320/1600 mg of TMP/SMX twice daily | 12 weeks | 2% |  | 0.3% |
20 weeks | 20Â weeks | 1% | Â | 3% | |||||
Chetchotisakd et al. [37] | RCT | 1.Co-trimoxazole, placebo | 311 | Double blind | TMP-SMX (80 mg TMP and 400 mg SMX) tablets were prescribed using a weight-based dose, bodyweight less than 40 kg or eGFR 15–29 mL/min, 160 mg TMP and 800 mg SMX twice daily; bodyweight of 40 kg to 60 kg, 240 mg TMP and 1200 mg SMX twice daily; and bodyweight greater than 60 kg, 320 mg TMP and 1600 mg SMX twice daily | 20 weeks | 16% | 3% | 3% |
2.Co-trimoxazole, Doxycycline | 315 | 21% | 8% | 1% | |||||
Chetchotisakd et al. [4] | RCT | 1. Ciprofloxacin and azithromycin | 32 | Open | Co- trimoxazole (10mg TMP + 50mg SMX/kg/day in 2 divided doses) | 12 weeks | 22% |  | 3.12% |
2. Co-trimoxazole and doxycycline | 33 | 20Â weeks | 3% | Â | 0% | ||||
Chaowagal et al. [38] | RCT | 1. Co-trimoxazole, doxycycline, chloramphenicol | 91 | Open | Co- trimoxazole (8mg TMP and 40mg SMX/kg/ daily; max 160mg TMP and 800mg SMX/twice daily | 12Â weeks | 2% | 5.9% | 4.4% |
 | 2.Doxycycline | 89 | 5.6% | 13% | 6.74% |